Biomea Fusion, Inc. (BMEA)

12.35 +0.42 (+3.52%) 收市：04:00PM EDT

Biomea Fusion, Inc.

900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com

版塊: Healthcare
行業: Biotechnology
全職員工: 110

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Thomas Andrew Butler	Co-Founder, Chairman & CEO	950.41k	無	1981
Mr. Ramses M. Erdtmann	Co-Founder, President, COO & Director	無	無	1963
Mr. Franco Valle	CFO & Principal Accounting Officer	673.66k	無	1981
Dr. Juan Pablo Frias M.D.	Chief Medical Officer	492.25k	無	無
Mr. Heow Tan	Chief Technology & Quality Officer	無	無	1959
Ms. Naomi Cretcher	Chief People Officer	無	無	無
Dr. Thorsten Kirschberg Ph.D.	Executive Vice President of Chemistry	無	無	1970
Dr. Stephan Morris M.D.	Chief Development Officer	無	無	無
Mr. Ravi Upasani	Executive Vice President of Intellectual Property	無	無	無
Caroline Perez- Dupont	Senior Vice President of Contracts	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

公司管治

截至 2024年5月1日 止，Biomea Fusion, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：6；董事會：9；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。